Primary cardiac lymphoma
Primary cardiac lymphoma
复制标题
DOI：
10.1016/j.ijcard.2010.02.016
复制
发表时间：
2011-06-16
影响因子：
3.5
通讯作者：
Bestetti, Reinaldo B.
中科院分区：
文献类型：
--
作者：
Miguel, Carlos E.;Bestetti, Reinaldo B.
原发性心脏淋巴瘤（PCL）是一种非常罕见的疾病。从组织学角度来看，大多数 PCL 病例是弥漫性 B 细胞淋巴瘤。 PCL 在免疫功能低下的患者中更常见。症状可能因涉及的心脏部位而异。与 PCL 相关的最常见的心脏临床表现是心包积液、心力衰竭和房室传导阻滞（AV 传导阻滞）。 PCL 的诊断可以通过经食管超声心动图、计算机断层扫描和磁共振成像来提示。然而，心脏肿瘤或心包积液的细胞学检查对于明确诊断这种情况至关重要。 PCL 的预后较差，初次诊断后中位生存期为 7 个月。包括利妥昔单抗免疫疗法或自体干细胞移植在内的新疗法有望治疗这种致命疾病。 (c) 2010 Elsevier Ireland Ltd. 保留所有权利。
Primary cardiac lymphoma (PCL) is a very rare disorder. Histologically, the majority of cases of PCL are diffuse B-cell lymphoma. PCL occurs more frequently in immunocompromised patients. Symptoms may vary according to the heart site involved. The most frequent cardiac clinical manifestations associated with PCL are pericardial effusion, heart failure, and atrioventricular block (AV-block). Diagnosis of PCL can be suggested by transesophageal echocardiography, computed tomography, and magnetic resonance imaging. However, cytologic examination of cardiac tumor or pericardial effusion is paramount for a definite diagnosis of this condition. Prognosis of PCL is poor with a median survival of 7 months after initial diagnosis. Newer modalities including immunotherapy with rituximab or auto stem cell transplantation are promising in the treatment of this lethal condition. (c) 2010 Elsevier Ireland Ltd. All rights reserved.